Depression in patients with cancer. Diagnosis and treatment in clinical practice Review article

Article Sidebar

PDF (Język Polski)


Published: Sep 26, 2012
Keywords:
cancer, depression, diagnosis, pharmacotherapy

Main Article Content

Sławomir Murawiec
Mokotowski Zespół Leczenia Domowego, Instytut Psychiatrii i Neurologii w Warszawie

Abstract

Comorbidity between depression and cancer is a common condition. It depends on many variables such as cancer location or phase of the illness, but as a rule this situation should not be neglected. The reasons for providing diagnosis and treatment in patients with cancer and depression are to diminish suffering of the ill person and to improve the outcome of the treatment. It is known based on scientific literature that the rates of mortality are higher in patients with both cancer and depression. Depression has negative effect on patients adherence to diagnostic and therapeutical procedures. Complains of depressed patients can have detrimental effect on professional satisfaction of oncologist. Another important reason for diagnosing patients with depression are higher economical burden of this group of patients caused by this condition to the health system. The paper presents data about the incidence of depression in cancer patients, the diagnostic criteria of depression and basic information about its pharmacological treatment.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Murawiec S. Depression in patients with cancer. Diagnosis and treatment in clinical practice. OncoReview [Internet]. 2012Sep.26 [cited 2024Nov.23];2(3(7):201-8. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/314
Issue
Vol 2 No 3(7) (2012)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Jabłoński M., Furgał M., Dudek D., Zięba A.: Miejsce psychoonkologii we współczesnej psychiatrii. Psychiatr. Pol. 2008; 42: 749-765.
2. van Esch L., Roukema J.A., Ernst M.F., de Nieuwenhuijzen J.: Combined anxiety and depressive symptoms before diagnosis of breast cancer. J. Affect. Disord. 2012; 136: 895-901.
3. Pössel P., Adams E., Valentine J.C.: Depression as a risk factor for breast cancer: investigating methodological limitations in the literature. Cancer Causes Control 2012; 23: 1223-1229.
4. Ng G.C., Boks M.P.M., Zainal N.Z., de Wit N.J.: The prevalence and pharmacotherapy of depression in cancer patients. J. Affect. Disord. 2011; 131: 1-7.
5. Onitilo A.A., Nietert P.J., Egede L.E.: Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen. Hosp. Psychiatr. 2006; 28: 396-402.
6. Kryszkowski W., Bobińska K., Florkowski A., Pluta P., Gottwald L., Gałecki P.: Wpływ farmakoterapii przeciwdepresyjnej na przebieg choroby nowotworowej. Psychiatr. Pol. 2012; 46: 85-94.
7. Lloyd-Williams M., Shiels C., Taylor F., Dennis M.: Depression – an independent predictor of early death in patients with advanced cancer. J. Affect. Disord. 2009; 113(1-2): 127-132.
8. ICD-10 Klasyfikacja Zaburzeń Psychicznych i Zaburzeń Zachowania. Opisy kliniczne i wskazówki diagnostyczne. Uniwersyteckie Wydawnictwo Medyczne Vesalius. Instytut Psychiatrii i Neurologii, Kraków–Warszawa 2000.
9. Pużyński S.: Depresje. PZWL, Warszawa 1988.
10. Mitchell A.J., Lord K., Symonds P.: Which depressive symptoms are indicative of DSMIV depression in cancer settings? An analysis of the diagnostic significance of somatic and non-somatic symptoms. J. Affect. Disord. 2012; 138: 137-148.
11. Gross A.L., Gallo J.J., Eaton W.W.: Depression and cancer risk; 24 years of follow-up of the Baltimore epidemiologic catchment area sample. Cancer Causes Control 2010; 30: 669-678.
12. Jaeschke R.: Ból i depresja w chorobach nowotworowych. W: Ból i depresja. Dudek D. (red.). Termedia, Poznań 2011: 103-118.
13. Polsky D., Doshi J.A., Marcus S., Oslin D., Rothbard A., Thomas N. et al.: Long-term risk for depressive symptoms after a medical diagnosis. Arch. Intern. Med. 2005; 165: 1260-1266.
14. Mitchell A.J., Chan M., Bhatti H., Halton M., Grassi L., Johansen C., Meader N.: Prevalence of depression, anxiety and adjustment disorders in oncological, haematological and palliative- care settings: a meta-analysis of 94 interview-based studies. Lancet Oncology 2011; 12: 160-174.
15. Massie M.J.: Prevalence of depression in patient with cancer. J. Natl. Cancer Inst. Monogr. 2004; 32: 57-71.
16. Shekelle R.B., Raynor Jr W., Ostfeld A.M., Garron D.C., Bieliauskas L.A., Liu S.C. et al.: Psychological depression and 17-year risk of death from cancer. Psychosom. Med. 1981; 43: 117-125.
17. Loberiza Jr F.R., Rizzo J.D., Bredeson C.N., Antin J.H., Horowitz M.M., Weeks J.C. et al.: Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J. Clin. Oncol. 2002; 20: 2118-2126.
18. Stommel M., Given B.A., Given C.W.: Depression and functional status as predictors of death among cancer patients. Cancer 2002; 94: 2719-2727.
19. Herrmann C., Brnad-Driehorst S., Kaminsky B., Leibling E., Staats H., Ruger U.: Diagnostic groups and depressed mood as predictors of 22-month mortality in medical inpatients. Psychosom. Med. 1998; 60: 570-577.
20. Watson M., Haviland J.S., Greer S., Davidson J., Bliss J.M.: Influence of psychological response on survival in breast cancer; a population-based cohort study. Lancet 1999; 354: 1331-1336.
21. Rabe-Jabłońska J., Miller A.: Związki między bólem a depresją. Psychiatr. Pol. 2005; 39: 7-20.
22. Wasilewski D., Wojnar M., Chatizow J.: Depresja a ból: ogólnopolskie badanie epidemiologiczne. Psychiatr. Pol. 2010; 45: 435-445.
23. Dudek D.: Objawy bólowe w depresji. W: Ból i depresja. Dudek D. (red.). Termedia, Poznań 2011: 23-30.
24. Messay B., Lim A., Marsland A.L.: Current understanding of the bi-directional relationship of major depression with inflammation. Biol. Mood Anxiety Disord. 2012; 28(2): 4-8.
25. Stahl S.M.: Podstawy psychofarmakoterapii. Wydanie popr. i uzup. ViaMedica, Gdańsk 2008: 568.
26. Rybakowski J., Borkowska A.: Escitalopram – druga generacja inhibitorów transportera serotoniny? Psychiatr. Pol. 2004; 37: 227-239.
27. Burke W.J.: Escitalopram. Expert Opin. Investig. Drugs 2002; 11: 1477-1486.
28. Park H.Y., Lee B.J., Kiom J.H., Bae J.N., Hahm B.J.: Rapid improvement of depression and quality of life with citalopram treatment in outpatients with breast cancer: a 12-week, open label prospective trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012; 36: 318-323.